Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.46 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.35 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16395990 | 0.89 | MAPT (0.46) | PTPN2MAPK14STING1HDAC3HDAC4 | |
| SCHEMBL16395966 | 0.86 | GPR35 (0.44) | GPR35BCL2L1PTPN2STING1HDAC3 | |
| SCHEMBL16396080 | 0.83 | GPR35 (0.46) | GPR35BCL2L1PTPN2MAPK14STING1 | |
| SCHEMBL16396235 | 0.83 | PTPN2 (0.48) | GPR35BCL2L1PTPN2MAPK14STING1 | |
| SCHEMBL16396069 | 0.81 | STING1 (0.54) | GPR35MAPK14STING1HDAC3HDAC4 | |
| SCHEMBL16396067 | 0.81 | GPR35 (0.46) | GPR35BCL2L1PTPN2MAPK14STING1 | |
| SCHEMBL16396294 | 0.78 | GPR35 (0.36) | GPR35BCL2L1PTPN2STING1 | |
| SCHEMBL34471930 | 0.77 | GPR35 (0.63) | GPR35BCL2L1PTPN2STING1MEN1 | |
| SCHEMBL17842813 | 0.77 | GPR35 (0.63) | GPR35BCL2L1PTPN2STING1MEN1 | |
| SCHEMBL16396914 | 0.76 | MAPT (0.44) | PTPN2STING1HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562912-B2 | Heterocyclic derivatives and use thereof | C&C RESEARCH LABORATORIES (KR) | 2020-02-18 | — | — | US | disclosed |
| EP-3004057-B1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS STAT 3 INHIBITORS | C&C RES LAB (KR) | 2018-07-25 | — | — | EP | disclosed |
| US-20160108056-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C RESEARCH LABORATORIES (KR) | 2016-04-21 | — | — | US | disclosed |
| EP-3004057-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C Research Laboratories (KR) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014196793-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C RESEARCH LABORATORIES (KR) | 2014-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108056-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | STAT3, JAK2, STAT5A | GPR35 2270/4885BCL2L1 786/4885PTPN2 329/4885 |
| US-10562912-B2 | Heterocyclic derivatives and use thereof | STAT3, JAK2, STAT5A | GPR35 2270/4885BCL2L1 786/4885PTPN2 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.